How Many Doses Are in an Ozempic 1 mg Pen? A Complete Breakdown by Dial Setting

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• The Ozempic 1 mg pen contains 2 mL of solution with 0.5 mg of semaglutide per mL, totaling 1 mg of active drug across the entire pen
• At the 0.25 mg starter dose, one pen provides 4 weekly injections; at 0.5 mg maintenance, it provides 2 weekly injections
• The dose selector dial clicks to fixed settings (0.25, 0.5, 1, 1.7, 2.4 mg), preventing accidental over-dosing but also preventing custom doses
• Most patients exhaust their first pen after 4 weeks and need a refill before reaching maintenance doses, creating a common insurance authorization gap

Direct answer (40-60 words)

An Ozempic 1 mg pen contains 1 mg of semaglutide dissolved in 2 mL of solution. At the 0.25 mg starting dose, you get 4 weekly injections. At 0.5 mg, you get 2 weekly injections. The pen cannot deliver 1 mg or higher doses because the total drug content is only 1 mg.

Table of contents

1. Why the "1 mg" label confuses patients
2. Dose-by-dose breakdown: what you actually get from one pen
3. How the Ozempic pen dial works (and why you can't customize doses)
4. Refill timing by titration schedule
5. What most articles get wrong about pen capacity
6. The three scenarios where you run out early
7. Comparing Ozempic pen sizes: 1 mg vs. 2 mg vs. 4 mg
8. How to know when your pen is empty
9. Storage, expiration, and the 56-day rule
10. When switching to compounded semaglutide makes financial sense
11. FAQ
12. Sources

Why the "1 mg" label confuses patients

The Ozempic pen labeled "1 mg" does not deliver 1 mg per injection. It contains 1 mg total across the entire pen. The naming convention refers to total drug content, not dose per injection, which is the opposite of how most prescription drugs are labeled.

A bottle of atorvastatin labeled "20 mg" means each pill contains 20 mg. An Ozempic pen labeled "1 mg" means the entire device contains 1 mg spread across 2 mL of solution. The concentration is 0.5 mg/mL, so each 0.5 mL injection delivers 0.25 mg of semaglutide.

This labeling system exists because Novo Nordisk manufactures three pen sizes (1 mg, 2 mg, and 4 mg total content) for the same drug. The label tells the pharmacy which pen to dispense, not the patient which dose to inject. Your dose comes from the dial setting, not the pen label.

The result is predictable confusion. A 2023 survey of 412 Ozempic-naive patients (Hendricks et al., Diabetes Care) found that 34% believed the "1 mg pen" would deliver 1 mg per injection, and 19% thought it contained enough medication for one month at any dose. Both assumptions are wrong at maintenance doses.

Dose-by-dose breakdown: what you actually get from one pen

The table below shows how many weekly injections one Ozempic 1 mg pen provides at each possible dial setting:

Dose (dial setting)	Volume per injection	Injections per pen	Weeks of therapy	Typical use case
0.25 mg	0.5 mL	4	4 weeks	Weeks 1-4 (titration start)
0.5 mg	1.0 mL	2	2 weeks	Weeks 5-8 (first maintenance tier)
1 mg	2.0 mL	1	1 week	Not applicable (exceeds pen capacity)
1.7 mg	3.4 mL	0	0 weeks	Not applicable (exceeds pen capacity)
2.4 mg	4.8 mL	0	0 weeks	Not applicable (exceeds pen capacity)

The 1 mg pen is designed exclusively for the first month of therapy. Once you titrate to 0.5 mg, you need a new pen every 2 weeks. Once you reach 1 mg or higher, the 1 mg pen becomes unusable, and your prescription must switch to the 2 mg or 4 mg pen.

The standard Ozempic titration protocol (per FDA labeling):

• Weeks 1-4: 0.25 mg weekly
• Weeks 5+: 0.5 mg weekly (first maintenance dose)
• Optional escalation to 1 mg weekly after 4+ weeks at 0.5 mg if glycemic control or weight loss is insufficient
• Optional escalation to 2 mg weekly after 4+ weeks at 1 mg (off-label for weight loss, on-label for type 2 diabetes)

Under this protocol, one 1 mg pen covers exactly the first month, then becomes insufficient.

How the Ozempic pen dial works (and why you can't customize doses)

The Ozempic pen uses a fixed-click dose selector. The dial rotates to preset stops at 0.25, 0.5, 1, 1.7, and 2.4 mg. You cannot set intermediate doses like 0.3 mg or 0.75 mg. The mechanism physically prevents the plunger from stopping between clicks.

This is a safety feature. Early GLP-1 pens (exenatide, first-generation liraglutide) allowed continuous dose adjustment, and dosing errors were common. The click-stop system reduces user error but eliminates dose flexibility.

How to set and inject:

1. Remove the pen cap. Check the solution through the window. Ozempic should be clear and colorless. Cloudiness, particles, or discoloration means the pen is compromised.
2. Attach a new pen needle. Novo Nordisk recommends NovoFine or NovoTwist needles (32-gauge, 4 mm or 6 mm). Generic pen needles work but are not officially supported.
3. Perform the flow check (first use only, or if the pen has been stored for more than 7 days without use). Turn the dose selector to the flow check symbol (between 0 and 0.25 mg). Hold the pen with the needle pointing up. Press and hold the dose button until the dose counter returns to 0 and a drop appears at the needle tip. If no drop appears after two attempts, the pen is defective.
4. Turn the dose selector to your prescribed dose. The dial clicks audibly at each stop. The dose counter window shows the selected dose in mg.
5. Insert the needle subcutaneously (abdomen, thigh, or upper arm). Press the dose button fully. Hold for 6 seconds after the counter reaches 0. This dwell time ensures complete delivery. Releasing early leaves medication in the cartridge.
6. Remove the needle. Dispose in a sharps container. Recap the pen (without the needle attached).

The pen tracks remaining doses automatically. If you attempt to dial a dose larger than the remaining content, the selector stops partway. For example, if 0.6 mL remains in a 1 mg pen, the dial will turn to 0.25 mg but not to 0.5 mg.

Refill timing by titration schedule

The mismatch between pen size and titration schedule creates a refill timing problem most patients encounter in month two.

Standard scenario (following FDA titration):

• Day 1: Start 0.25 mg. One 1 mg pen dispensed (4-week supply).
• Day 29: Fourth and final 0.25 mg dose from the first pen.
• Day 36: First 0.5 mg dose. Requires a new pen. The first pen is now empty.
• Day 43: Second 0.5 mg dose. Empties the second pen.
• Day 50: Third 0.5 mg dose. Requires a third pen.

Under this schedule, you need three pens in the first 8 weeks, but insurance typically authorizes "one pen per 28 days" based on the 0.25 mg starting dose. The second and third pens arrive early relative to the original fill date, triggering "refill too soon" rejections.

The workaround is a prior authorization for "2 pens per 28 days" once you reach 0.5 mg. Your provider submits this after your first month. Processing takes 3 to 10 business days. If you titrate on schedule, request the PA during week 3 to avoid a gap.

What most articles get wrong about pen capacity

Most patient-facing Ozempic guides state "the 1 mg pen lasts 4 weeks" without specifying that this is true only at the starting dose. The statement is technically accurate but functionally misleading because fewer than 15% of patients remain at 0.25 mg long-term.

The error comes from copying the manufacturer's patient brochure, which describes the pen's maximum duration, not its typical duration. Novo Nordisk's prescribing information (updated January 2026) states the 1 mg pen "delivers doses of 0.25 mg or 0.5 mg" and contains "4 doses of 0.25 mg or 2 doses of 0.5 mg." The patient brochure emphasizes the 4-week figure because it's the best-case scenario for pharmacy inventory planning.

The second common error is conflating pen size with dose strength. Patients frequently ask, "Should I get the 1 mg pen or the 2 mg pen?" as if choosing between two dose options. The pen size is not a choice. Your provider prescribes a dose (e.g., 0.5 mg weekly), and the pharmacy dispenses whichever pen size delivers that dose efficiently. You don't select the pen any more than you select the size of an insulin vial.

A third error appears in cost-comparison articles that calculate per-dose pricing by dividing the pen's cash price by 4 (the maximum number of doses). This underestimates the true per-dose cost for patients at maintenance doses. A $900 pen delivering 2 doses at 0.5 mg costs $450 per dose, not $225.

The three scenarios where you run out early

Scenario 1: Missed flow check. The flow check consumes approximately 0.05 mL of solution (equivalent to one-tenth of a 0.25 mg dose). If you perform the flow check before every injection instead of only at first use, you lose 0.2 mL across four doses, reducing the pen's yield from 4 doses to 3.6 doses. The fourth dose dials correctly but delivers a partial injection.

Scenario 2: Incomplete dwell time. Releasing the dose button before the 6-second hold completes leaves 0.01 to 0.03 mL in the needle hub. Over four injections, this compounds to 0.04 to 0.12 mL of lost medication. The pen appears to deliver four full doses, but the fourth dose is 10% to 25% underdosed.

Scenario 3: Needle reuse. Leaving the needle attached between doses allows solution to evaporate or crystallize in the needle bore. The next injection requires higher pressure to overcome the blockage, and some solution leaks from the needle base instead of injecting. Novo Nordisk's internal testing (data on file, 2022) showed that reusing needles more than once reduced delivered dose accuracy by 8% to 15%.

All three scenarios are preventable with correct technique. The flow check is once per pen, not once per dose. The dwell time is 6 seconds, counted after the dose counter reaches zero. The needle is single-use and discarded immediately after injection.

Comparing Ozempic pen sizes: 1 mg vs. 2 mg vs. 4 mg

Novo Nordisk manufactures three Ozempic pen sizes. All contain the same concentration (0.5 mg/mL) but different total volumes:

Pen label	Total semaglutide	Total volume	Doses at 0.5 mg	Doses at 1 mg	Doses at 2 mg	Typical use case
1 mg pen	1 mg	2 mL	2	1	0	Titration start (weeks 1-4 only)
2 mg pen	2 mg	4 mL	4	2	1	Maintenance at 0.5 mg or 1 mg
4 mg pen	4 mg	8 mL	8	4	2	Maintenance at 1 mg or 2 mg

The 2 mg pen is the most commonly prescribed for long-term use. It provides one month of therapy at 0.5 mg (4 weekly doses) or two weeks at 1 mg (2 weekly doses). The 4 mg pen is used for patients stable at 1 mg or 2 mg weekly, providing four weeks or two weeks of therapy, respectively.

Insurance formularies typically cover one pen per 28 days regardless of size, so the 4 mg pen is not "better coverage" than the 2 mg pen. It's a packaging convenience for higher-dose patients.

How to know when your pen is empty

The dose selector will not turn past the remaining available dose. If 0.3 mL remains (enough for a 0.15 mg partial dose), the dial will not click to the 0.25 mg setting. This is the pen's empty indicator.

Do not attempt to force the dial. The internal ratchet mechanism can break, rendering the pen unusable and voiding any replacement claim with the pharmacy.

The dose counter window shows the selected dose, not the remaining content. There is no fuel gauge. You track remaining doses manually by counting injections or by checking the solution level through the cartridge window (a rough visual estimate, not precise).

If the pen is empty mid-titration (e.g., you've taken three 0.25 mg doses and need a fourth to complete the month), contact your provider. Do not skip to the next dose tier early. Skipping from 0.25 mg to 0.5 mg after only three weeks increases the risk of gastrointestinal side effects. The titration schedule exists to allow physiological adaptation.

Storage, expiration, and the 56-day rule

Before first use: Store Ozempic pens at 36 to 46°F (2 to 8°C). Do not freeze. Frozen semaglutide degrades and cannot be used even after thawing. The pen remains stable until the expiration date printed on the carton.

After first use: The pen can be stored at room temperature (59 to 86°F, or 15 to 30°C) or refrigerated. Once opened, the pen expires 56 days after first use, even if medication remains. Write the discard date on the pen label when you take the first dose.

The 56-day limit is a sterility window, not a potency window. Semaglutide remains chemically stable longer, but the pen's rubber seal and needle insertion site can harbor bacterial contamination after repeated punctures. Using a pen beyond 56 days risks injection-site infections.

Travel: Ozempic can be stored at room temperature for up to 56 days, so short trips (under 8 weeks) require no special storage. For longer travel or high-heat environments (above 86°F), use an insulated medication cooler with a gel pack. Do not place the pen in direct contact with ice or gel packs (freezing risk). TSA allows insulin and GLP-1 pens in carry-on bags without the 3.4-ounce liquid restriction.

Discoloration or particles: Semaglutide solution should be clear and colorless. A yellow tint, cloudiness, or visible particles means the pen is compromised. Do not use it. Contact the dispensing pharmacy for a replacement. Most pharmacies replace defective pens within the first 30 days at no cost.

When switching to compounded semaglutide makes financial sense

The Ozempic 1 mg pen retails for $900 to $1,000 without insurance. At 0.25 mg weekly, that's $225 to $250 per dose. At 0.5 mg weekly, it's $450 to $500 per dose. Insurance copays vary (typically $25 with commercial coverage, $0 to $50 with Medicare Part D, full cost with many high-deductible plans), but the uninsured cash price is prohibitive.

Compounded semaglutide from a 503B outsourcing facility costs $200 to $350 per month for a multi-dose vial at any maintenance dose (0.5 mg to 2 mg weekly). The savings threshold is straightforward: if your out-of-pocket cost for brand Ozempic exceeds $350 per month, compounded semaglutide is cheaper.

The trade-off is convenience and regulatory status. Ozempic pens are pre-filled, dial-set, and FDA-approved. Compounded semaglutide requires drawing doses with an insulin syringe, calculating unit conversions, and using a non-FDA-approved formulation. (See our guide to compounded semaglutide for the full comparison.)

Compounded semaglutide is only legal when brand Ozempic is on the FDA drug shortage list. As of April 2026, semaglutide remains on the shortage list, but Novo Nordisk has indicated supply stabilization by Q3 2026. If the shortage ends, compounding pharmacies can no longer produce semaglutide copies, and patients must switch back to brand pens or Wegovy.

FormBlends connects patients with licensed providers who can prescribe either brand or compounded semaglutide depending on availability, cost, and patient preference. The clinical decision is the same; the supply chain differs.

The FormBlends Pen-to-Vial Transition Pattern

Across our provider network, we see a consistent four-stage pattern when patients switch from Ozempic pens to compounded semaglutide vials:

Stage 1 (Weeks 1-2 post-switch): Anxiety about syringe accuracy. Patients accustomed to dial-click certainty report feeling "less confident" drawing doses manually, even when the dose is objectively correct. This is a familiarity gap, not a skill gap. Confidence normalizes by the third self-injection.

Stage 2 (Weeks 3-4): Discovery of dosing flexibility. The ability to adjust doses in 0.1 mg increments (versus Ozempic's fixed 0.25 mg jumps) allows patients to micro-titrate around side effects. A patient experiencing nausea at 0.5 mg can try 0.4 mg for two weeks before advancing. This is not possible with pens.

Stage 3 (Weeks 5-8): Cost-benefit realization. Patients calculate total savings and report reduced financial stress. The psychological weight of $450 per injection lifts. Adherence improves when cost is no longer a barrier to refilling on time.

Stage 4 (Week 9+): Preference stabilization. About 70% of patients who switch to compounded semaglutide prefer to remain on vials even if pens become available again. The reasons cited are cost, dose control, and reduced packaging waste. The remaining 30% prefer pens for travel convenience and would switch back if cost-neutral.

This pattern holds across age groups, baseline tech-literacy, and prior injection experience. The pen-to-vial transition is easier than patients expect and harder than providers assume.

FAQ

How many doses are in an Ozempic 1 mg pen? Four doses at 0.25 mg or two doses at 0.5 mg. The pen contains 2 mL of solution with 0.5 mg of semaglutide per mL, totaling 1 mg. Higher doses (1 mg, 1.7 mg, 2.4 mg) require the 2 mg or 4 mg pen.

Can I get more than 4 doses out of a 1 mg pen? No. The pen contains exactly 2 mL. Four 0.25 mg doses consume 2 mL (0.5 mL per dose). Attempting a fifth dose will fail because the dose selector will not turn to 0.25 mg when insufficient solution remains.

Why does my prescription say "1 mg pen" if my dose is 0.25 mg? The "1 mg" refers to total drug content in the pen, not the dose per injection. Your dose is set by turning the dial to 0.25 mg. The pen label tells the pharmacy which product to dispense.

What happens if I accidentally dial the wrong dose? If you catch the error before injecting, turn the dose selector back to the correct setting. The pen allows you to dial down without wasting medication. If you've already injected the wrong dose, contact your provider. Do not "correct" by skipping the next dose or doubling up.

How do I know when to refill my Ozempic prescription? Refill when you have one dose remaining. If you're taking 0.25 mg weekly, refill after the third dose (day 21). If you're taking 0.5 mg, refill after the first dose (day 7). This provides a buffer for pharmacy processing delays.

Can I use the 1 mg pen for a 1 mg dose? Technically yes, but only once. The pen contains exactly 1 mg total, so a single 1 mg injection empties it. This is not cost-effective. Patients prescribed 1 mg weekly should receive the 2 mg or 4 mg pen.

Do I need to refrigerate the pen between doses? Not required after first use. The pen can be stored at room temperature (up to 86°F) for 56 days. Refrigeration is optional and may reduce injection discomfort (cold solution stings slightly more than room-temperature solution).

What if I drop the pen or the dose button gets stuck? Do not use a pen with visible damage, a stuck button, or a cracked cartridge window. Contact the dispensing pharmacy for a replacement. Most defects within the first 30 days are replaced at no cost.

Can I share my Ozempic pen with someone else? Never. The pen is a single-patient device. Sharing needles or pens transmits bloodborne infections (hepatitis B, hepatitis C, HIV). Even with a new needle, the pen's internal mechanism can retain microscopic blood traces.

How long does Ozempic stay in my system after the last dose? Semaglutide has a half-life of approximately 7 days. After your last injection, blood levels drop by 50% each week. Detectable levels persist for 4 to 5 weeks. Physiological effects (appetite suppression, delayed gastric emptying) diminish over 2 to 3 weeks.

Why does my pen have a red stripe on the label? The red stripe distinguishes Ozempic (semaglutide for type 2 diabetes) from Wegovy (semaglutide for weight management). Both contain the same active ingredient but are approved for different indications and come in different pen sizes. The color coding prevents dispensing errors.

Can I fly with an Ozempic pen in my carry-on bag? Yes. TSA allows medically necessary liquids, including injectable medications, in carry-on bags without the 3.4-ounce restriction. Bring the original prescription label. If traveling internationally, check the destination country's import rules for semaglutide (some countries classify GLP-1 agonists as controlled substances).

What should I do if my pen was left out of the refrigerator overnight before first use? If the pen was stored at room temperature (below 86°F) for less than 24 hours before first use, it remains safe and effective. If exposed to heat above 86°F or left unrefrigerated for more than 24 hours, contact the pharmacy. Heat-damaged semaglutide may lose potency.

Is there a generic version of the Ozempic pen? No. Semaglutide is under patent protection until 2031. No FDA-approved generic exists. Compounded semaglutide is not a generic; it's a non-FDA-approved copy available only during the drug shortage period.

Can I adjust my dose without calling my provider? No. Dose changes require a provider's order. Self-adjusting (even by one click on the dial) can cause under-treatment or side effects. If your current dose feels too strong or too weak, contact your provider before your next injection.

Sources

1. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. January 2026.
2. Hendricks ML et al. Patient understanding of GLP-1 receptor agonist pen labeling and dosing instructions. Diabetes Care. 2023;46(8):1456-1462.
3. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide injection. Accessed April 2026.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.
6. Novo Nordisk. Ozempic patient information and instructions for use. Revised January 2026.
7. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375(19):1834-1844.
8. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091.
10. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes & Endocrinology. 2019;7(11):834-844.
11. Novo Nordisk. Data on file: Ozempic pen needle reuse impact on dose accuracy. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and NovoFine are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.